Literature DB >> 3291903

Repopulation in human tumors. A biological background for fractionation in radiotherapy.

M Tubiana1.   

Abstract

Tumor repopulation plays a major role in the response of tumors to radiotherapy or chemotherapy but its degree varies widely among human tumors. Its mechanism has not been elucidated, however it is unlikely that repopulation can be simply explained by the greater availability of oxygen and nutrients resulting from the reduction in tumor mass. In normal tissues, such as bone marrow, treated cells release stimulating factors which are able to recruit quiescent cells into proliferation. Similar mechanisms have been observed in experimental tumors and their existence is probable in human tumors. A low pretreatment proliferation index and low cell density indicate that the control mechanisms which regulate cell proliferation in normal tissues are still partially operating in these tumors. In such tumors an increase in the level of cell proliferation during or after treatment has often, but not always, been observed. There is not yet a clear guide for predicting tumor proliferation rate under treatment and further investigations are needed.

Entities:  

Mesh:

Year:  1988        PMID: 3291903     DOI: 10.3109/02841868809090328

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  13 in total

1.  Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN.

Authors:  D E Hallahan; V P Sukhatme; M L Sherman; S Virudachalam; D Kufe; R R Weichselbaum
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

2.  Cell proliferation in human tumours growing in nude mice: renal cell carcinomas, larynx and hypopharynx carcinomas.

Authors:  B Maurer-Schultze; I D Bassukas; M Böswald; M Harasim
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Tumour repopulation and the role of abortive division in squamous cell carcinomas during chemotherapy.

Authors:  L G Marcu
Journal:  Cell Prolif       Date:  2014-05-13       Impact factor: 6.831

4.  Treatment of the rat R-1 rhabdomyosarcoma with methotrexate and radiation; effects of timing on cell survival and tumour growth delay.

Authors:  J B Kipp; H B Kal; A H van Gennip; A H van Berkel
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Elevated cleaved caspase-3 is associated with shortened overall survival in several cancer types.

Authors:  Qian Hu; Jing Peng; Weiping Liu; Xiaoli He; Ling Cui; Xinlian Chen; Mei Yang; Hongqian Liu; Shanling Liu; He Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

Review 6.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04

7.  Duration of radiation therapy is associated with worse survival in head and neck cancer.

Authors:  Angela L Mazul; Katelyn O Stepan; Thomas F Barrett; Wade L Thorstad; Sean Massa; Douglas R Adkins; Mackenzie D Daly; Jason T Rich; Randal C Paniello; Patrik Pipkorn; Jose P Zevallos; Ryan S Jackson; Stephen Y Kang; Sidharth V Puram
Journal:  Oral Oncol       Date:  2020-05-30       Impact factor: 5.337

8.  Mathematical modeling of the Phoenix Rising pathway.

Authors:  Chad Liu; Chuan-Yuan Li; Fan Yuan
Journal:  PLoS Comput Biol       Date:  2014-02-06       Impact factor: 4.475

9.  Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy.

Authors:  Anne L Donato; Qian Huang; Xinjian Liu; Fang Li; Mary A Zimmerman; Chuan-Yuan Li
Journal:  J Invest Dermatol       Date:  2014-01-16       Impact factor: 8.551

10.  Fusion between M2-macrophages and cancer cells results in a subpopulation of radioresistant cells with enhanced DNA-repair capacity.

Authors:  Annelie Lindström; Kristine Midtbö; Lars-Gunnar Arnesson; Stina Garvin; Ivan Shabo
Journal:  Oncotarget       Date:  2017-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.